Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Merus B.V.
Incyte Corporation
Akeso
DEKA Biosciences
Taproot Health
Celldex Therapeutics
Glycotope GmbH
Daiichi Sankyo
Amgen